Evidence map›Paper›PMID 38112481›Full record

ArticleMicrobiology spectrum2024

Pharmacokinetic/pharmacodynamic integration of amphenmulin: a novel pleuromutilin derivative against

Wenxiang Wang, Jiao Yu, Xuan Ji, Xirui Xia, Huanzhong Ding

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Natural Products AgainstMicroorganisms · 2026
    Review
  2. Article
  3. ComprehensiveFrontiers in veterinary science · 2025
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Wenxiang WangGuangdong Key Laboratory for Veterinary Drug Development and Safety Evaluation, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China.ORCID 0009-0002-9542-7746
Jiao YuGuangdong Key Laboratory for Veterinary Drug Development and Safety Evaluation, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China.
Xuan JiGuangdong Key Laboratory for Veterinary Drug Development and Safety Evaluation, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China.
Xirui XiaGuangdong Key Laboratory for Veterinary Drug Development and Safety Evaluation, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China.
Huanzhong DingGuangdong Key Laboratory for Veterinary Drug Development and Safety Evaluation, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China.ORCID 0000-0002-0123-1228
South China Agricultural University · CN

Funding

Guangdong Basic and Applied Basic Research Foundation 2022A1515010997
6 · The paper itself

Abstract

Amphenmulin is a novel pleuromutilin derivative with great anti-mycoplasma potential. The present study evaluated the action characteristics of amphenmulin against

Indexed as

Anti-Infective AgentsMycoplasma gallisepticumPoultry DiseasesAnimalsAnti-Bacterial AgentsChickensHumansMicrobial Sensitivity TestsPleuromutilinsAnti-Bacterial AgentsAnti-Infective AgentsPleuromutilinsin vitro dynamic modelMycoplasma gallisepticumpharmacodynamicspharmacokineticspleuromutilin

Identifiers

PMID38112481
PMCPMC10846240
OpenAlexW4389948911

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.